Mount Sinai’s latest innovation in the fight against cancer is set to revolutionize how patients are connected to clinical trials. In a groundbreaking effort to improve accessibility to cutting-edge cancer treatments, Mount Sinai Health System has launched a new AI-powered platform designed to match cancer patients with relevant clinical trials. This move aims to significantly increase participation in clinical trials, one of the most effective ways to discover new cancer treatments.
Why this AI tool matters:
Clinical trials have long been a critical component in the fight against cancer. However, despite the vast number of cancer trials, only a small fraction of eligible patients participate. According to Dr. Karyn Goodman, a leading oncologist at Mount Sinai, the hospital only enrolls about 10% of eligible patients into clinical trials each year, with many doctors and patients unaware of the trials they qualify for.
Mount Sinai’s new AI platform, named PRISM, uses an oncology large language model developed by Triomics to streamline the process of identifying patients who are eligible for clinical trials. This automated system reviews electronic medical records (EMR) to quickly and accurately find the best candidates, reducing the manual work traditionally required and enhancing the speed at which patients can be matched to trials.
AI and clinical trials: A new era of healthcare
AI has made significant strides in healthcare, with applications ranging from diagnostics to patient care. Now, the focus is on accelerating the recruitment process for clinical trials. Mount Sinai’s PRISM platform represents a major leap forward, allowing doctors to identify potential participants with ease and providing them with more treatment options.
The AI system has the potential to improve the accuracy of matching patients to clinical trials, ensuring that the most relevant therapies are offered. This not only helps in advancing research but also provides cancer patients with the opportunity to access new treatments that could save their lives.
Equity in healthcare: Expanding access to trials
The introduction of AI technology in clinical trial matching also has profound implications for healthcare equity. One of the key goals of the PRISM platform is to make clinical trials more accessible to diverse populations. Dr. Goodman highlights that by using AI to identify eligible patients, Mount Sinai can ensure that all demographics, including underserved communities, have access to cutting-edge cancer therapies.
This AI-driven approach is particularly important as it addresses several barriers that have traditionally limited access to clinical trials, such as geographical location, lack of awareness, and the complexity of navigating trial databases.
Global impact: What’s at stake
The AI platform has the potential to not only improve cancer treatment outcomes but also reduce the overall healthcare burden. If successfully implemented on a global scale, this system could save billions in healthcare costs by expediting the process of identifying effective treatments and reducing the time and resources needed to recruit participants.
Looking ahead: The future of cancer research and treatment
As AI continues to evolve, it will play an increasingly central role in both patient care and clinical research. Mount Sinai’s PRISM platform is an important step in this direction, and with its implementation, the hope is that more patients will be able to access the clinical trials that could potentially change their lives.
